| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2015124877 |
| Title |
Derivatives of 5-Benzylisoquinoline for The Treatment of Cardiovascular Diseases. |
| Abstract |
The invention relates to novel isoquinoline derivatives of formula (I), to the synthesis thereof, and to the use of same in the prevention and/or treatment of pathologies resulting from the activation of the RhoA/ROCK pathway and the phosphorylation of the light chain of myosin. X represents a group -C(=0)-, -CH(OH)- or -CH2-, and the other substituents represent various groups such as those defined in claim 1. |
| Applicant(s) |
Les Laboratoires Servier |
| Representative Drug(s) |
D0S0VF |
Drug Info
|
IC50 = 6 nM |
Click to Show More |
[1] |
|
2
|
D08YGE
|
Drug Info
|
IC50 = 9 nM
|
[1] |
| Patent ID |
WO2014055996 |
| Title |
Rho Kinase Inhibitors. |
| Abstract |
The invention relates to inhibitors of ROCKl and/or ROCK2. Also provided are methods of treating diseases and disorders involving inhibiting ROCKl and/or ROCK2. |
| Applicant(s) |
Kadmon Corporation, Llc |
| Representative Drug(s) |
D0DO1U |
Drug Info
|
N.A. |
Click to Show More |
[1] |
|
2
|
D0QX0O
|
Drug Info
|
N.A.
|
[1] |
| Patent ID |
WO2013112722 |
| Title |
Inhibitors of Rho Associated Protein Kinases (Rock) and Methods of Use. |
| Abstract |
Compounds and compositions having activity as inhibitors of Rho-associated proteinkinases (ROCKs), and methods of making and using the subject compounds are disclosed. |
| Applicant(s) |
H. Lee Moffitt Cancer Center and Research Institute |
| Representative Drug(s) |
D0CW9Q |
Drug Info
|
IC50 = 650 nM |
[1] |
| Patent ID |
WO2011062765 |
| Title |
1,4-Benzodiazepine-2,5-Diones and Related Compounds with Therapeutic Properties. |
| Abstract |
The present invention provides novel chemical compounds characterized as Rho kinase (ROCK) inhibitors, methods for their discovery, and their therapeutic, research, and diagnostic use. In particular, the present invention provides 1,4-benzodiazepine-2,5-dione compounds and related compounds having ROCK inhibitory activity, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with ROCK activity. |
| Applicant(s) |
The Regents of the University of Michigan |
| Representative Drug(s) |
D0QC6H |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2016057306 |
| Title |
Rho Associated Kinase (Rock) Inhibitors and Their Use In Treating Disease. |
| Abstract |
The present disclosure describes peptide inhibitors of Rho-associtated-kinase (ROCK) and their use in treating disorders including heart failure, the leading cause of combined morbidity and mortality in the United States. An inhibitory polypeptide blocks ROCK1 activity in the presence of 1 mM ATP. The binding epitope on ROCK1 was mapped using chemical cross-linking to the Activation Loop, a novel locus identifying a new class of inhibitory drugs. The peptides described will be useful against a number of important diseases such as heart disease, pulmonary hypertension, arterial hypertension, gluacoma management, insulin resistance, kidney disease, hemolytic anemia, stroke, ischemia reperfusion injury, or acute mycloid leukemia. |
| Applicant(s) |
University of Houston System |
| Patent ID |
WO2006105081 |
| Title |
Pharmacokinetically Improved Compounds. |
| Abstract |
The present invention relates to inhibitors of ROCKl and R0CK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCKl and or R0CK2 that are useful for the treatment of disease. |
| Applicant(s) |
Surface Logix, Inc |
